| Patient | Jacqueline Mary du Pré |
|---|---|
| Date of birth | 1945-01-26 |
| Identifiers | MRN HR-ML039-SYN-TD; SSN (made up) 000-39-7062 |
| Document date | 2026-11-01 |
| Author | Imogen Thackeray-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three weeks of numbness and clumsiness in the fingers of both hands, with Lhermitte's sign and fatigue, in a professional cellist of 28: examination, blood tests, and urgent MRI of the brain and spine. Concerns: For three weeks the fingers of both hands have been numb and tingling, worse on the left; she cannot feel the strings properly, loses her place on the fingerboard and has dropped her bow twice; an electric feeling runs down her back when she bends her head; tired by mid-afternoon for months; A similar month of tingling in her fingers 18 months ago was put down to overwork and stress, and settled; She wants to know what is wrong, and whether she will be able to play again. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Nitrofurantoin macrocrystals 100 mg oral capsule, one capsule by mouth twice daily with food for 5 days | One capsule twice daily for 5 days | Oral route | 1973-06-15 to 1973-06-19 | completed | S |
| Methylprednisolone 1000 mg injection, 1 g intravenously over one hour once daily for 3 days | 1 g daily for 3 days | Intravenous route | 1973-03-24 to 1973-03-26 | completed | S |
| Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth daily | One capsule daily | Oral route | 1973-03-23 | active | S |
| Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion | 300 mg on days 1 and 15, then 600 mg every 6 months | Intravenous route | 1973-04-13 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| MRI of the brain with and without gadolinium: 11 ovoid T2-hyperintense lesions, 3 mm to 9 mm, eight periventricular (several perpendicular to the ventricles), two juxtacortical and one in the right middle cerebellar peduncle; one periventricular lesion enhances; most lesions show a central vein; no mass, no meningeal enhancement | 1973-03-12 to 1973-03-12 | completed | S |
| MRI of the cervical and thoracic spine with and without gadolinium (same session): a short dorsal lesion at C3 to C4, less than one vertebral segment long and occupying under half the cord's cross-section, with patchy enhancement; a second, non-enhancing lesion at T7; no cord swelling or compression | 1973-03-12 to 1973-03-12 | completed | S |
| Lumbar puncture: clear fluid; white cells 6 per microliter (lymphocytes), protein 42 mg/dL, glucose normal; six oligoclonal bands in the cerebrospinal fluid not present in the serum; IgG index 0.86 (raised). Serum aquaporin-4 IgG by cell-based assay negative; HIV and syphilis serology negative | 1973-03-16 to 1973-03-16 | completed | S |
| Advance care planning conversation, about 15 minutes | 1973-09-14 to 1973-09-14 | completed | S |
| Occupational therapy assessment and program for hand function and fatigue: fine-motor and sensory re-education exercises for the fingers, graded return to practice in short blocks with rests, posture at the instrument, and energy management | 1973-03-30 to 1973-03-30 | completed | S |
| Re-baseline MRI of the brain with and without gadolinium three months after starting ocrelizumab: no new or enlarging T2 lesions and no enhancing lesions; the previously enhancing periventricular lesion is smaller | 1973-07-08 to 1973-07-08 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1970-02-06 | Tdap vaccine | completed | S |
| 1973-09-14 | Influenza vaccine, this season (inactivated) | completed | S |
| 1973-09-14 | COVID-19 mRNA vaccine, this season's formula | completed | S |
| 1973-03-23 | Pneumococcal conjugate vaccine (PCV20), before B-cell therapy | completed | S |
| 1973-03-23 | Recombinant zoster vaccine, dose 1 of 2, before B-cell therapy | completed | S |
| 1973-03-23 | Hepatitis B vaccine (adjuvanted, two-dose series), dose 1, before B-cell therapy | completed | S |
| 1973-04-27 | Hepatitis B vaccine (adjuvanted, two-dose series), dose 2 | completed | S |
| 1973-07-13 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
No historical medical events are recorded.
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| For three weeks the fingers of both hands have been numb and tingling, worse on the left; she cannot feel the strings properly, loses her place on the fingerboard and has dropped her bow twice; an electric feeling runs down her back when she bends her head; tired by mid-afternoon for months | active | S |
| A similar month of tingling in her fingers 18 months ago was put down to overwork and stress, and settled | active | S |
| She wants to know what is wrong, and whether she will be able to play again | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 13.7 on 1973-10-12; Leukocytes [#/volume] in Blood by Automated count 6 on 1973-10-12; Lymphocytes [#/volume] in Blood by Automated count 1.4 on 1973-10-12; Platelets [#/volume] in Blood by Automated count 238 on 1973-10-12; Sodium [Moles/volume] in Serum or Plasma 140 on 1973-03-09; Potassium [Moles/volume] in Serum or Plasma 4.2 on 1973-03-09; Creatinine [Mass/volume] in Serum or Plasma 0.7 on 1973-10-12; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1968)/1.73 sq M 121 on 1973-10-12; Glucose [Mass/volume] in Serum or Plasma 90 on 1973-04-27; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 on 1973-10-12; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 on 1973-10-12; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 468 on 1973-03-09; Thyrotropin [Units/volume] in Serum or Plasma 1.6 on 1973-03-09; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1973-03-09; 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] 18.5 on 1973-10-12; 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] 19.5 on 1973-10-12; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 38 on 1973-10-12; IgG [Mass/volume] in Serum or Plasma 930 on 1973-10-12; IgM [Mass/volume] in Serum or Plasma 46 on 1973-10-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1973-10-12; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 3 on 1973-10-12; C reactive protein [Mass/volume] in Serum or Plasma 14 on 1973-06-15; CD19 cells [#/volume] in Blood 3 on 1973-07-13; Hepatitis B virus surface Ab [Units/volume] in Serum 6 on 1973-10-12 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this week | resolved | confirmed | R20.2 | S — Synthetic presenting problem anchored to her documented loss of sensation in her fingers and fatigue. Superseded by the diagnosis at the second visit. |
| Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 1964 McDonald criteria and the 1971 revision; synthetic modern detail linked to her documented diagnosis | active | confirmed | G35.A | S — Synthetic course, imaging and laboratory detail; linked to her documented diagnosis in October 1973. |
| Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosis | active | confirmed | E55.9 | S — Synthetic finding. |
| Acute uncomplicated cystitis (Escherichia coli) seven weeks after the first ocrelizumab course, with a pseudo-relapse: two days of returning tingling in the fingers with a low fever and no new neurological deficit; resolved | resolved | confirmed | N30.00 | S — Synthetic intercurrent infection; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1973-03-09 | Hemoglobin [Mass/volume] in Blood | 13.4 | g/dL | 12-15.5 g/dL | Normal | S |
| 1973-03-09 | Leukocytes [#/volume] in Blood by Automated count | 6.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1973-03-09 | Lymphocytes [#/volume] in Blood by Automated count | 1.9 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 1973-03-09 | Platelets [#/volume] in Blood by Automated count | 246 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1973-03-09 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1973-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1973-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.72 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1973-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1968)/1.73 sq M | 117 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1973-03-09 | Glucose [Mass/volume] in Serum or Plasma | 86 | mg/dL | 70-99 mg/dL | Normal | S |
| 1973-03-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 16 | U/L | 7-35 U/L | Normal | S |
| 1973-03-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | 8-35 U/L | Normal | S |
| 1973-03-09 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 468 | pg/mL | 232-1245 pg/mL | Normal | S |
| 1973-03-09 | Thyrotropin [Units/volume] in Serum or Plasma | 1.6 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 1973-03-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1973-03-09 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 26 | s | S | ||
| 1973-03-09 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 33.5 | s | S | ||
| 1973-03-23 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 16 | ng/mL | Below 20 ng/mL deficient; 20 to 29 insufficient | Low | S |
| 1973-03-23 | IgG [Mass/volume] in Serum or Plasma | 1080 | mg/dL | 700-1600 mg/dL | Normal | S |
| 1973-03-23 | IgM [Mass/volume] in Serum or Plasma | 124 | mg/dL | 40-230 mg/dL | Normal | S |
| 1973-03-23 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 1973-03-23 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 1973-03-23 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 24.5 | s | S | ||
| 1973-03-23 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 31 | s | S | ||
| 1973-04-27 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 12-15.5 g/dL | Normal | S |
| 1973-04-27 | Leukocytes [#/volume] in Blood by Automated count | 7.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1973-04-27 | Lymphocytes [#/volume] in Blood by Automated count | 1.6 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 1973-04-27 | Platelets [#/volume] in Blood by Automated count | 252 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1973-04-27 | Glucose [Mass/volume] in Serum or Plasma | 90 | mg/dL | 70-99 mg/dL | Normal | S |
| 1973-04-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 7-35 U/L | Normal | S |
| 1973-04-27 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-35 U/L | Normal | S |
| 1973-04-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1973-04-27 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 20.5 | s | S | ||
| 1973-04-27 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 23 | s | S | ||
| 1973-06-15 | Leukocytes [#/volume] in Blood by Automated count | 10.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1973-06-15 | C reactive protein [Mass/volume] in Serum or Plasma | 14 | mg/L | <=5 mg/L | High | S |
| 1973-07-13 | Hemoglobin [Mass/volume] in Blood | 13.5 | g/dL | 12-15.5 g/dL | Normal | S |
| 1973-07-13 | Leukocytes [#/volume] in Blood by Automated count | 6.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1973-07-13 | Lymphocytes [#/volume] in Blood by Automated count | 1.5 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 1973-07-13 | Platelets [#/volume] in Blood by Automated count | 240 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1973-07-13 | CD19 cells [#/volume] in Blood | 3 | /uL | 100-500 /uL | Low | S |
| 1973-07-13 | IgG [Mass/volume] in Serum or Plasma | 990 | mg/dL | 700-1600 mg/dL | Normal | S |
| 1973-07-13 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | Below 20 ng/mL deficient; 20 to 29 insufficient | Normal | S |
| 1973-07-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 1973-07-13 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 19 | s | S | ||
| 1973-07-13 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 20.5 | s | S | ||
| 1973-09-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 1973-10-12 | Hemoglobin [Mass/volume] in Blood | 13.7 | g/dL | 12-15.5 g/dL | Normal | S |
| 1973-10-12 | Leukocytes [#/volume] in Blood by Automated count | 6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1973-10-12 | Lymphocytes [#/volume] in Blood by Automated count | 1.4 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 1973-10-12 | Platelets [#/volume] in Blood by Automated count | 238 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1973-10-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1973-10-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1968)/1.73 sq M | 121 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1973-10-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-35 U/L | Normal | S |
| 1973-10-12 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 8-35 U/L | Normal | S |
| 1973-10-12 | IgG [Mass/volume] in Serum or Plasma | 930 | mg/dL | 700-1600 mg/dL | Normal | S |
| 1973-10-12 | IgM [Mass/volume] in Serum or Plasma | 46 | mg/dL | 40-230 mg/dL | Normal | S |
| 1973-10-12 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 38 | ng/mL | Below 20 ng/mL deficient; 20 to 29 insufficient | Normal | S |
| 1973-10-12 | Hepatitis B virus surface Ab [Units/volume] in Serum | 6 | m[IU]/mL | 10 mIU/mL or more is protective | Low | S |
| 1973-10-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 1973-10-12 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | {score} | S | ||
| 1973-10-12 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 18.5 | s | S | ||
| 1973-10-12 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 19.5 | s | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1973-03-09 | Body height | 173 | cm | S |
| 1973-03-09 | Body weight | 63.5 | kg | S |
| 1973-03-09 | Body mass index (BMI) [Ratio] | 21.2 | kg/m2 | S |
| 1973-03-09 | Systolic blood pressure | 112 | mm[Hg] | S |
| 1973-03-09 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1973-03-09 | Heart rate | 74 | /min | S |
| 1973-03-09 | Respiratory rate | 14 | /min | S |
| 1973-03-09 | Body temperature | 36.6 | Cel | S |
| 1973-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1973-03-23 | Body height | 173 | cm | S |
| 1973-03-23 | Body weight | 63.4 | kg | S |
| 1973-03-23 | Body mass index (BMI) [Ratio] | 21.2 | kg/m2 | S |
| 1973-03-23 | Systolic blood pressure | 114 | mm[Hg] | S |
| 1973-03-23 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1973-03-23 | Heart rate | 76 | /min | S |
| 1973-03-23 | Respiratory rate | 14 | /min | S |
| 1973-03-23 | Body temperature | 36.7 | Cel | S |
| 1973-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1973-04-27 | Body height | 173 | cm | S |
| 1973-04-27 | Body weight | 64.6 | kg | S |
| 1973-04-27 | Body mass index (BMI) [Ratio] | 21.6 | kg/m2 | S |
| 1973-04-27 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1973-04-27 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1973-04-27 | Heart rate | 72 | /min | S |
| 1973-04-27 | Respiratory rate | 14 | /min | S |
| 1973-04-27 | Body temperature | 36.6 | Cel | S |
| 1973-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1973-07-13 | Body height | 173 | cm | S |
| 1973-07-13 | Body weight | 64 | kg | S |
| 1973-07-13 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 1973-07-13 | Systolic blood pressure | 110 | mm[Hg] | S |
| 1973-07-13 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1973-07-13 | Heart rate | 70 | /min | S |
| 1973-07-13 | Respiratory rate | 14 | /min | S |
| 1973-07-13 | Body temperature | 36.6 | Cel | S |
| 1973-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1973-10-12 | Body height | 173 | cm | S |
| 1973-10-12 | Body weight | 63.8 | kg | S |
| 1973-10-12 | Body mass index (BMI) [Ratio] | 21.3 | kg/m2 | S |
| 1973-10-12 | Systolic blood pressure | 112 | mm[Hg] | S |
| 1973-10-12 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1973-10-12 | Heart rate | 68 | /min | S |
| 1973-10-12 | Respiratory rate | 14 | /min | S |
| 1973-10-12 | Body temperature | 36.5 | Cel | S |
| 1973-10-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1973-06-15 | Body height | 173 | cm | S |
| 1973-06-15 | Body weight | 63.6 | kg | S |
| 1973-06-15 | Body mass index (BMI) [Ratio] | 21.3 | kg/m2 | S |
| 1973-06-15 | Systolic blood pressure | 116 | mm[Hg] | S |
| 1973-06-15 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1973-06-15 | Heart rate | 92 | /min | S |
| 1973-06-15 | Respiratory rate | 16 | /min | S |
| 1973-06-15 | Body temperature | 37.8 | Cel | S |
| 1973-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1973-09-14 | Body height | 173 | cm | S |
| 1973-09-14 | Body weight | 63.9 | kg | S |
| 1973-09-14 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 1973-09-14 | Systolic blood pressure | 110 | mm[Hg] | S |
| 1973-09-14 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1973-09-14 | Heart rate | 68 | /min | S |
| 1973-09-14 | Respiratory rate | 14 | /min | S |
| 1973-09-14 | Body temperature | 36.6 | Cel | S |
| 1973-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1973-03-09 | Three weeks of numbness and clumsiness in the fingers of both hands, with Lhermitte's sign and fatigue, in a professional cellist of 28: examination, blood tests, and urgent MRI of the brain and spine | finished | S |
| 1973-03-23 | Diagnosis of relapsing-remitting multiple sclerosis: neurology consultation, treatment of the relapse, choice of high-efficacy disease-modifying therapy, and vaccinations before B-cell therapy | finished | S |
| 1973-04-27 | Second half-dose of the first ocrelizumab course: recovery of hand function, infusion reactions, vaccination, practice and work | finished | S |
| 1973-07-13 | Three months on ocrelizumab: re-baseline MRI, B-cell depletion, fatigue, vitamin D and hand function | finished | S |
| 1973-10-12 | Six months: first 600 mg dose of ocrelizumab, no evidence of disease activity, immunoglobulins, vaccination response, pregnancy planning and her return to performing | finished | S |
| 1973-06-15 | Same-day sick visit for cystitis with a pseudo-relapse | finished | S |
| 1973-09-14 | Periodic adult preventive visit on B-cell therapy | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Neurology (multiple sclerosis) consultation within two weeks to review the MRI with her and make a diagnosis and plan | completed | GL-AAN-DMT-2018, GL-NICE-NG220 | S |
| Urgent work-up of a sensory syndrome of both hands with Lhermitte's sign: MRI of the brain and cervical and thoracic spine with gadolinium within a week; blood count, chemistry, vitamin B12 and TSH; lumbar puncture for oligoclonal bands if the MRI is suggestive; return at once for weakness, unsteadiness, loss of bladder control or loss of vision | completed | GL-MCDONALD-2017, GL-MAGNIMS-2021, GL-NICE-NG220 | S |
| Relapse treatment: methylprednisolone 1 g intravenously daily for three days for a relapse that limits her hand function, after excluding infection; occupational therapy for hand function and energy management | completed | GL-NICE-NG220, GL-ECTRIMS-2018 | S |
| Early high-efficacy disease-modifying therapy with ocrelizumab: 300 mg intravenously on days 1 and 15, then 600 mg every six months, with premedication; chosen over natalizumab because the JCV antibody is positive and over ofatumumab at her preference for twice-yearly infusions; before the first dose, hepatitis B screening, varicella and measles immunity, immunoglobulins, a pregnancy test, and inactivated vaccines at least two weeks ahead; contraception during treatment | completed | GL-AAN-DMT-2018, GL-ECTRIMS-2018, GL-OPERA-2017, GL-AAN-VACC-2019 | S |
| Vitamin D: cholecalciferol 4000 units daily to correct deficiency, with a level after three months; not as a treatment for multiple sclerosis | completed | GL-NICE-NG220 | S |
| Monitoring on ocrelizumab: re-baseline MRI of the brain three to six months after starting, then yearly; blood count and immunoglobulins before each dose; infection and pseudo-relapse teaching; pregnancy planning, with conception timed after a dose | completed | GL-MAGNIMS-2021, GL-ECTRIMS-2018, GL-AAN-DMT-2018 | S |
| Fatigue, mood and work: screening for depression and sleep problems at each visit, plain explanations with written information, and a plan built around her practice, performing and teaching; she decides who is told and who receives each note | completed | GL-NICE-NG220, GL-USPSTF-DEP-2023 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| MRI of the brain and spine within one week and a neurology diagnosis within three weeks | 1973-03-23 | completed | MRI in three days, lumbar puncture in a week, diagnosis and consultation at two weeks | S |
| High-efficacy disease-modifying therapy started within six weeks of diagnosis, after screening and vaccinations | 1973-04-27 | completed | Ocrelizumab started three weeks after the diagnosis; PCV20, recombinant zoster and hepatitis B vaccines given first | S |
| Nine-hole peg times back to within 10 percent of normal in both hands, and full practice resumed | 1973-07-13 | completed | 19.0 seconds right and 20.5 seconds left at three months; practicing three hours a day | S |
| No evidence of disease activity at six months (no relapse, no new or enhancing MRI lesion, no disability progression) | 1973-10-12 | completed | No relapse; re-baseline MRI with no new or enhancing lesions; examination stable | S |
| 25-hydroxyvitamin D of 30 ng/mL or more | 1973-07-13 | completed | 34 ng/mL after 16 weeks of cholecalciferol | S |
| PHQ-9 below 10 throughout | 1973-10-12 | completed | PHQ-9 between 3 and 7 | S |